{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:47:39Z","timestamp":1790398059675,"version":"4.1.0"},"reference-count":11,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>With 400,000 new cases and over 80,000 deaths a year worldwide, endometrial cancer (EC) holds a rather unfortunate record, namely, that of the tumour with the highest increase in incidence, a unique trend among gynaecological cancers [...]<\/jats:p>","DOI":"10.3390\/ijms24076462","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T02:23:46Z","timestamp":1680143026000},"page":"6462","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["New Strategies for Endometrial Cancer Detection and Management"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6176-2979","authenticated-orcid":false,"given":"Laura","family":"Paleari","sequence":"first","affiliation":[{"name":"Research, Innovation and HTA Unit, A.Li.Sa., Liguria Health Authority, 16121 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"ref_1","unstructured":"(2023, March 10). American Cancer Society: Key Statistics for Endometrial Cancer. Available online: https:\/\/www.cancer.org\/cancer\/endometrial-cancer\/about\/key-statistics.html."},{"key":"ref_2","unstructured":"(2023, March 10). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/uterine.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Paleari, L., Rutigliani, M., Siri, G., Provinciali, N., Colombo, N., and DeCensi, A. (2020). Aromatase Inhibitors as Adjuvant Treatment for ER\/PgR Positive Stage I Endometrial Carcinoma: A Retrospective Cohort Study. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062227"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Alessandro, L., Low, K.-J.E., Abushelaibi, A., Lim, S.-H.E., Cheng, W.-H., Chang, S.-K., Lai, K.-S., Sum, Y.W., and Maran, S. (2022). Identification of NRAS Diagnostic Biomarkers and Drug Targets for Endometrial Cancer\u2014An Integrated in Silico Approach. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232214285"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Celsi, F., Monasta, L., Arrigoni, G., Battisti, I., Licastro, D., Aloisio, M., Di Lorenzo, G., Romano, F., Ricci, G., and Ura, B. (2022). Gel-Based Proteomic Identification of Suprabasin as a Potential New Candidate Biomarker in Endometrial Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23042076"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Benbrook, D.M., Hocker, J.R.S., Moxley, K.M., and Hanas, J.S. (2022). Sera Protein Signatures of Endometrial Cancer Lymph Node Metastases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063277"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Arciuolo, D., Travaglino, A., Raffone, A., Raimondo, D., Santoro, A., Russo, D., Varricchio, S., Casadio, P., Inzani, F., and Seracchioli, R. (2022). TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911684"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Paleari, L., Pesce, S., Rutigliani, M., Greppi, M., Obino, V., Gorlero, F., Vellone, V.G., and Marcenaro, E. (2021). New Insights into Endometrial Cancer. Cancers, 13.","DOI":"10.3390\/cancers13071496"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Schiemer, R., Furniss, D., Phang, S., Seddon, A.B., Atiomo, W., and Gajjar, K.B. (2022). Vibrational Biospectroscopy: An Alternative Approach to Endometrial Cancer Diagnosis and Screening. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094859"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e003777","DOI":"10.1136\/jitc-2021-003777","article-title":"Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient\/microsatellite instability-high (dMMR\/MSI-H) or proficient\/stable (MMRp\/MSS) endometrial cancer: Interim results from GARNET-a phase I, single-arm study","volume":"10","author":"Oaknin","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.2217\/fon-2021-0598","article-title":"Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer","volume":"17","author":"Oaknin","year":"2021","journal-title":"Future Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6462\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:06:40Z","timestamp":1760123200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":11,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ijms24076462"],"URL":"https:\/\/doi.org\/10.3390\/ijms24076462","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]}}}